TuHURA Biosciences (HURA) Expected to Announce Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is expected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect TuHURA Biosciences to post earnings of ($0.09) per share for the quarter.

TuHURA Biosciences Trading Up 0.9 %

NASDAQ:HURA opened at $3.33 on Monday. TuHURA Biosciences has a 1-year low of $2.84 and a 1-year high of $14.60. The company’s fifty day simple moving average is $4.37.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HURA. Maxim Group assumed coverage on TuHURA Biosciences in a research report on Tuesday, November 5th. They set a “buy” rating and a $15.00 price target on the stock. RODMAN&RENSHAW raised TuHURA Biosciences to a “strong-buy” rating in a research report on Thursday, December 19th. Finally, Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock.

Institutional Trading of TuHURA Biosciences

A hedge fund recently bought a new stake in TuHURA Biosciences stock. Bank of America Corp DE purchased a new position in shares of TuHURA Biosciences (NASDAQ:HURA) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 14,314 shares of the company’s stock, valued at approximately $59,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.